Stocks | |||||
The table gives an overview of all stocks, alphabetically sorted. | |||||
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z |
Name | Symbol | Analysis date | Close | +/- % |
Cumulus Media A | CMLS | Nov 27, 2024 | 0.76 | +10.39 |
Curbline Properties | CURB | Nov 27, 2024 | 24.43 | 0.00 |
Curevac N.V. | CVAC | Nov 27, 2024 | 2.87 | +4.74 |
CuriosityStream | CURI | Nov 27, 2024 | 1.83 | 0.00 |
Curis | CRIS | Nov 27, 2024 | 4.45 | +10.42 |
CURRENC Group | CURR | Nov 27, 2024 | 1.76 | 0.00 |
Curtiss-Wright | CW | Nov 27, 2024 | 371.37 | -0.98 |
Cushing Mlp & Infrastructure Total Return Fund | SRV | Nov 27, 2024 | 45.37 | +1.68 |
Cushman & Wakefield | CWK | Nov 27, 2024 | 15.48 | +1.64 |
Custom Truck One Source | CTOS | Nov 27, 2024 | 6.00 | +3.45 |
Customers Bancorp | CUBI | Nov 27, 2024 | 56.84 | +0.48 |
Customers Bancorp E Pref | CUBI-E | Nov 27, 2024 | 25.94 | -0.90 |
Customers Bancorp F Pref | CUBI-F | Nov 27, 2024 | 25.83 | +0.19 |
Cutera | CUTR | Nov 27, 2024 | 0.46 | +16.58 |
CVB Financial | CVBF | Nov 27, 2024 | 23.83 | 0.00 |
CVD Equipment | CVV | Nov 27, 2024 | 3.03 | -3.50 |
CVR Energy | CVI | Nov 27, 2024 | 19.27 | +0.68 |
Cvr Partners LP Unit | UAN | Nov 27, 2024 | 75.77 | +7.83 |
CVRx | CVRX | Nov 27, 2024 | 15.31 | +0.07 |
CVS Health | CVS | Nov 27, 2024 | 59.96 | +1.61 |
CXApp A | CXAI | Nov 27, 2024 | 1.59 | +4.61 |
CyberArk Software | CYBR | Nov 27, 2024 | 318.78 | -2.81 |
Cybin | CYBN | Nov 27, 2024 | 10.25 | -4.30 |
Cyclacel Pharmaceuticals | CYCC | Nov 27, 2024 | 0.34 | -2.54 |
Cyclacel Pharmaceuticals Pref | CYCCP | Nov 27, 2024 | 6.75 | -2.74 |
Cyclerion Therapeutics | CYCN | Nov 27, 2024 | 2.16 | +58.82 |
Cyclo Therapeutics | CYTH | Nov 27, 2024 | 0.72 | +6.04 |
Cyngn | CYN | Nov 27, 2024 | 6.01 | -5.95 |
Cytek Biosciences | CTKB | Nov 27, 2024 | 6.50 | +1.40 |
Cytokinetics | CYTK | Nov 27, 2024 | 52.22 | +0.38 |
Investtech guarantees neither the entirety nor accuracy of the analyses. Any consequent exposure related to the advice / signals which emerge in the analyses is completely and entirely at the investors own expense and risk. Investtech is not responsible for any loss, either directly or indirectly, which arises as a result of the use of Investtechs analyses. Details of any arising conflicts of interest will always appear in the investment recommendations. Further information about Investtechs analyses can be found here disclaimer.
The content provided by Investtech.com is NOT SEC or FSA regulated and is therefore not intended for US or UK consumers.
Investtech guarantees neither the entirety nor accuracy of the analyses. Any consequent exposure related to the advice / signals which emerge in the analyses is completely and entirely at the investors own expense and risk. Investtech is not responsible for any loss, either directly or indirectly, which arises as a result of the use of Investtechs analyses. Details of any arising conflicts of interest will always appear in the investment recommendations. Further information about Investtechs analyses can be found here disclaimer.
The content provided by Investtech.com is NOT SEC or FSA regulated and is therefore not intended for US or UK consumers.